Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic Pipeline and Expand Depth and Breadth of Commercial OfferingsJune 4, 2024
Results from evaluation of the company’s SpliceCore® AI/ML platform in Triple Negative Breast Cancer published in Molecular Systems BiologyApril 25, 2024
Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration AgreementDecember 13, 2022
Oxford Global – Biologics Analysis – Insight Article – The Black Box Effect – How Can AI and ML Provide Transparent Insights for Drug Discovery?August 30, 2022
Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy DevelopmentAugust 2, 2022
Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery PlatformSeptember 29, 2021
Envisagenics Announces Research Program with the Lung Cancer Initiative at Johnson & JohnsonJanuary 21, 2020
Envisagenics wins another SBIR grant from the National Cancer Institute to enhance their AI/ML platform for Immunotherapy developmentJanuary 13, 2020
Innovation in Health Symposiums, Promote Holistic Health and Cutting-Edge Solutions Super Bowl WeekEIN Presswire - January 30, 2025
2023 forecast: An ‘inflection point’ for biopharma, fueled by a flood of AI and machine learning productsFierece Pharma - December 21, 2022
M12 and VC partners award $3.5 million to most innovative companies harnessing the power of artificial intelligenceWebWire Press Release - May 1, 2018
Envisagenics closes $2.35M seed round and launches SpliceCore Platform for identifying RNA targets from splicing errorsRNA-Seq Blog - November 29, 2017
This program gives hot startups free office space in New York City for a year — meet this year’s winnersBusiness Insider - July 12, 2016
Startup Envisagenics Nabs NIH Grant to Develop Alternative Splicing Analysis TechGenomeWeb - August 13, 2015